CVTX CV Therapeutics (MM)

PALO ALTO, Calif., Aug. 24 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (NASDAQ:CVTX) announced today that seven abstracts featuring healthcare cost data, a clinical study and several preclinical studies have been accepted for presentation at the European Society of Cardiology (ESC)/World Congress of Cardiology (WCC) taking place in Barcelona, Spain from September 2-6, 2006. Abstracts include: Ranexa(R): -- Alterations in T-wave morphology caused by ranolazine are not pro- arrhythmic in dofetilide susceptible chronic AV-block dogs. Poster; Final Program #4408; Tuesday, September 5, 2:00 - 6:00 p.m. (Central European Summer Time-CEST). Late Sodium Current: -- Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone in an experimental model. Oral; Final Program #1979; Monday, September 4, 11:00 - 11:15 a.m. (CEST). -- Predictors of quinidine-induced torsade de pointes: role of late sodium current. Poster; Final Program #4404; Tuesday, September 5, 2:00 - 6:00 p.m. (CEST). Cost of Angina: -- Differences in healthcare resource use between coronary artery disease (CAD) patients with and without angina. Poster; Final Program #3959; Tuesday, September 5, 8:30 a.m. - 12:30 p.m. (CEST). Regadenoson: -- Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by PET. Oral; Final Program #1203: Sunday, September 3, 4:45-5:00 p.m. (CEST). -- Effects of caffeine on coronary vasodilation and sinus tachycardia induced by regadenoson, a novel adenosine A2A receptor agonist, in conscious dogs. Poster; Final Program #2475; Monday, September 4, 12:30 - 1:30 p.m. (CEST). Tecadenoson -- Protective effect of the selective A1 adenosine receptor agonist CVT-510 (Tecadenoson) on recovery from myocardial stunning. Poster; Final Program #607; Sunday, September 3, 8:30 a.m. - 12:30 p.m. (CEST). In addition, on Tuesday, September 5, at the ESC/WCC in Barcelona, Spain, CV Therapeutics is sponsoring a satellite symposium entitled, Chronic Stable Angina: The Forgotten Patients in CV Medicine, chaired by Dr. Phillip Poole- Wilson of the UK and Dr. Jose Lopez Sendon of Spain and a Focus Session on refractory angina. Additional information regarding the ESC/WCC 2006 Scientific Sessions can be accessed at http://www.escardio.org/congresses/World_Congress_Cardiology_2006/Scientific/. About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics' approved products include Ranexa(R) (ranolazine extended- release tablets) and ACEON(R) (perindopril erbumine) Tablets. Ranexa is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates. In addition, CV Therapeutics co-promotes ACEON(R), an ACE inhibitor, for reduction of the risk of cardiovascular mortality or nonfatal myocardial infarction in patients with stable coronary artery disease and treatment of essential hypertension. CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies and CVT-6883, which is being developed as a potential treatment for asthma and other conditions. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use. Except for the historical information contained herein, the matters set forth in this press release, including statements as to development, conduct of clinical and preclinical studies, and study results, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, early stage of development; regulatory review and approval of our products; the conduct and timing of clinical and preclinical trials; commercialization of products; market acceptance of products; product labeling; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2006. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements. DATASOURCE: CV Therapeutics, Inc. CONTACT: Investors, Christopher Chai, Vice President, Treasury and Investor Relations, +1-650-384-8560, or Media, John Bluth, Senior Director, Corporate Communications, +1-650-384-8850, both of CV Therapeutics, Inc. Web site: http://www.escardio.org/ Web site: http://www.cvt.com/

Copyright